Pacific Biosciences of California, Inc. – NASDAQ:PACB
Pacific Biosciences of California stock price today
$1.329
-0.53
-28.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Pacific Biosciences of California stock price monthly change
+10.71%
month
Pacific Biosciences of California stock price quarterly change
+10.71%
quarter
Pacific Biosciences of California stock price yearly change
-81.57%
year
Pacific Biosciences of California key metrics
Market Cap | 517.41M |
Enterprise value | N/A |
P/E | -7.87 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 19.43 |
Price/Book | 4.42 |
PEG ratio | 0.13 |
EPS | -1.14 |
Revenue | 200.43M |
EBITDA | -282.61M |
Income | -296.89M |
Revenue Q/Q | -0.23% |
Revenue Y/Y | 49.54% |
Profit margin | -244.92% |
Oper. margin | -237.58% |
Gross margin | 38.22% |
EBIT margin | -237.58% |
EBITDA margin | -141% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePacific Biosciences of California stock price history
Pacific Biosciences of California stock forecast
Pacific Biosciences of California financial statements
| Jun 2023 | 47.57M | -69.83M | -146.79% |
|---|---|---|---|
| Sep 2023 | 55.69M | -66.86M | -120.07% |
| Dec 2023 | 58.35M | -82.01M | -140.55% |
| Mar 2024 | 38.81M | -78.17M | -201.44% |
| Sep 2025 | 89.35M | -55.75M | -62.4% |
|---|---|---|---|
| Oct 2025 | 61.25M | -48.93M | -79.89% |
| Dec 2025 | 66.34M | -47.73M | -71.94% |
| Mar 2026 | 62M | -48.52M | -78.26% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1847631000 | 1.20B | 65.25% |
|---|---|---|---|
| Sep 2023 | 1898354000 | 1.13B | 59.77% |
| Dec 2023 | 1746013000 | 1.04B | 59.83% |
| Mar 2024 | 1669920000 | 1.02B | 61.13% |
| Jun 2023 | -41.74M | -98.59M | -4.71M |
|---|---|---|---|
| Sep 2023 | -65.18M | 242.32M | -781K |
| Dec 2023 | -57.61M | -66.57M | -81.55M |
| Mar 2024 | -75.68M | -34.13M | 6.55M |
Pacific Biosciences of California alternative data
| Aug 2023 | 769 |
|---|---|
| Sep 2023 | 769 |
| Oct 2023 | 769 |
| Nov 2023 | 769 |
| Dec 2023 | 769 |
| Jan 2024 | 769 |
| Feb 2024 | 769 |
| Mar 2024 | 796 |
| Apr 2024 | 796 |
| May 2024 | 796 |
| Jun 2024 | 796 |
| Jul 2024 | 796 |
Pacific Biosciences of California other data
100.00%
+4.56%
of PACB is owned by hedge funds
232
-14
221.50M
+16.18M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 62038 |
| Sep 2023 | 0 | 126101 |
| Dec 2023 | 0 | 20000 |
| Jan 2024 | 0 | 31012 |
| Feb 2024 | 0 | 160964 |
| Mar 2024 | 40000 | 31606 |
| May 2024 | 0 | 5275 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | FARMER MICHELE officer: See Remarks | Common Stock | 5,275 | $2.03 | $10,708 | ||
Option | ORDONEZ KATHY director | Common Stock | 37,106 | $2.63 | $97,589 | ||
Option | ORDONEZ KATHY director | Common Stock | 324,515 | $2.9 | $941,094 | ||
Option | ORDONEZ KATHY director | Stock Option (right to buy) | 361,621 | $2.77 | $999,882 | ||
Purchase | MELINE DAVID W director | Common Stock | 40,000 | $4.4 | $176,160 | ||
Sale | FARMER MICHELE officer: See Remarks | Common Stock | 2,968 | $4.87 | $14,457 | ||
Sale | VAN OENE MARK officer: See Remarks | Common Stock | 9,186 | $4.87 | $44,745 | ||
Sale | KIM SUSAN G. officer: See Rema.. | Common Stock | 5,275 | $4.87 | $25,695 | ||
Sale | HENRY CHRISTIAN O officer: See Remarks | Common Stock | 14,177 | $4.87 | $69,056 | ||
Option | MOHR MARSHALL director | Common Stock | 25,000 | $4.45 | $111,250 |
| Patent |
|---|
Grant Filling date: 15 Mar 2021 Issue date: 16 Aug 2022 |
Application Filling date: 25 Oct 2021 Issue date: 11 Aug 2022 |
Application Filling date: 10 Nov 2021 Issue date: 28 Jul 2022 |
Grant Filling date: 24 Feb 2020 Issue date: 12 Jul 2022 |
Grant Filling date: 18 Sep 2020 Issue date: 5 Jul 2022 |
Grant Utility: Modified nucleotide reagents Filling date: 13 Jun 2019 Issue date: 14 Jun 2022 |
Application Filling date: 5 Nov 2021 Issue date: 2 Jun 2022 |
Application Filling date: 29 Oct 2021 Issue date: 2 Jun 2022 |
Application Filling date: 4 Oct 2021 Issue date: 2 Jun 2022 |
Application Filling date: 6 Oct 2021 Issue date: 26 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 30 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Christian O. Henry M.B.A. (1968) Pres, Chief Executive Officer & Director | $772,450 |
Dr. Denis Zaccarin Ph.D. (1965) Senior Vice President of R&D | $440,430 |
| Ms. Susan G. Kim (1977) Chief Financial Officer | $238,870 |
How To Pick Top Pharma Stocks: Novo Nordisk And More
Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value
Reassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market Dynamics
Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market
Assessing Pacific Biosciences And Their Revio Launch
Singular Genomics: Betting On Expanding Genomics Systems Market
Illumina, Pacific Biosciences, And Oxford Nanopore Market Position Comparison
Bruker Corp.: My Top Ranked Holding In Laboratory Analytical Instruments
-
What's the price of Pacific Biosciences of California stock today?
One share of Pacific Biosciences of California stock can currently be purchased for approximately $1.33.
-
When is Pacific Biosciences of California's next earnings date?
Unfortunately, Pacific Biosciences of California's (PACB) next earnings date is currently unknown.
-
Does Pacific Biosciences of California pay dividends?
No, Pacific Biosciences of California does not pay dividends.
-
How much money does Pacific Biosciences of California make?
Pacific Biosciences of California has a market capitalization of 517.41M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 56.29% to 200.52M US dollars.
-
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California, Inc. is traded on the NASDAQ under the ticker symbol "PACB".
-
What is Pacific Biosciences of California's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Pacific Biosciences of California?
Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the following people:
- Mr. Christian O. Henry M.B.A. Pres, Chief Executive Officer & Director(age: 57, pay: $772,450)
- Dr. Denis Zaccarin Ph.D. Senior Vice President of R&D(age: 60, pay: $440,430)
- Ms. Susan G. Kim Chief Financial Officer(age: 48, pay: $238,870)
-
How many employees does Pacific Biosciences of California have?
As Jul 2024, Pacific Biosciences of California employs 796 workers.
-
When Pacific Biosciences of California went public?
Pacific Biosciences of California, Inc. is publicly traded company for more then 14 years since IPO on 27 Oct 2010.
-
What is Pacific Biosciences of California's official website?
The official website for Pacific Biosciences of California is pacb.com.
-
Where are Pacific Biosciences of California's headquarters?
Pacific Biosciences of California is headquartered at 1305 O’Brien Drive, Menlo Park, CA.
-
How can i contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O’Brien Drive, Menlo Park, CA and company can be reached via phone at +65 05218000.
Pacific Biosciences of California company profile:
Pacific Biosciences of California, Inc.
pacb.comExchange:
NASDAQ
Full time employees:
796
Industry:
Medical - Devices
Sector:
Healthcare
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
1305 O’Brien Drive
Menlo Park, CA 94025
Menlo Park, CA 94025
CIK: 0001299130
ISIN: US69404D1081
CUSIP: 69404D108
